Seeking Alpha

FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection (MCD) Test

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough ...
Business Wire

Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types

Blood-based Shield Multi-Cancer Detection (MCD) test exhibits high specificity, clinically meaningful sensitivity and strong cancer signal of origin accuracy Results informed National Cancer Institute ...
Seeking Alpha

First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test

Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participants Shield MCD reviewed by FDA as part of NCI’s investigational device ...